Actively Recruiting
Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy
Led by Yunfeng Xia · Updated on 2025-12-18
392
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis. Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.
CONDITIONS
Official Title
Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 75 years with stage 5 chronic kidney disease
- Receiving maintenance hemodialysis for more than 3 months
- Undergoing regular dialysis three times a week
- Have a relatively stable condition and can care for themselves
- Willing to cooperate with the study
- Can understand and use WeChat and the "Yueya" mini-program proficiently
You will not qualify if you...
- Patients unable to cooperate due to communication barriers or other reasons
- History of acute myocardial infarction, cerebral infarction, or intracerebral hemorrhage within the past six months
- Unwillingness to actively cooperate with the study
- Severe liver cirrhosis, active tuberculosis, or AIDS
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016
Actively Recruiting
Research Team
Y
Yunfeng Xia Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here